Skip to content

Robot-Assisted Surgery versus craniotomy for adult supratentorial IntraCerebral Hemorrhage (RASICH): a randomized controlled trial

Robot-Assisted Surgery versus craniotomy for adult supratentorial IntraCerebral Hemorrhage (RASICH): a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088316
Enrollment
Unknown
Registered
2024-08-15
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracerebral hemorrhage

Interventions

Robot-assisted surgery group:The neuronsurgeon will perform a hematoma evacuation with the assistance of a robot
Craniotomy group:The surgeon will perform a craniotomy for hematoma evacuation

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 80 years; (2) GCS score between 6 and 14; (3) Admitted to the hospital and completed a head CT scan within 24 hours of onset; (4) CT-confirmed spontaneous supratentorial intracerebral hemorrhage; (5) Hematoma volume >= 30ml; (6) Randomization and surgery performed within 24 hours of admission; (7) Willing to participate in this study and have signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Secondary intracerebral hemorrhage related to aneurysm, AVM, moyamoya disease, tumors, trauma, etc.; (2) History of previous intracerebral hemorrhage; (3) Infratentorial hemorrhage; (4) Multiple intracranial hematomas; (5) Ventricular cast requiring ventricular hematoma evacuation; (6) Brain herniation requiring decompressive craniectomy; (7) Abnormal coagulation; (8) Pregnancy; (9) Specific medical contraindications to general anesthesia or surgery; (10) Other diseases may affect the final outcome (malignant tumors, cardiovascular diseases, etc.).

Design outcomes

Primary

MeasureTime frame
30-day mortality after surgery;

Secondary

MeasureTime frame
7-day rebleeding after surgery;30-day intracranial infection after surgery;30-day neurological outcomes after surgery;

Countries

China

Contacts

Public ContactLiu Yi

West China Hospital, Sichuan University

liuyi@wchscu.cn+86 189 8060 5815

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026